Groundbreaking GLP-1 drugs like Ozempic, Mounjaro and Wegovy are revolutionising weight loss, with studies showing ...
Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.
Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However, access and affordability vary drastically worldwide, with ...
A MAJOR review has pitted three blockbuster fat jabs against each other – comparing weight lost and how long users were able ...
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide ...
As demand for GLP-1 medications continues to skyrocket for weight loss and diabetes, more Americans are skipping pharmacies and turning to unregulated sellers as a way to avoid high prices, insurance ...
Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...
Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback